This phase 1 clinical study is evaluating the safety and efficacy of the study medication, DONQ52.
This medication is designed to target an immune complex known to cause celiac disease symptoms. This may protect the small intestine of a person with celiac disease.
There is no gluten challenge in this study. You may be compensated for time and travel.
- You are 18-65 years old
- You have celiac disease
- You are already on a gluten-free diet
- You have had a diagnostic biopsy
- Other requirements will apply.
If you’re interested in the study, think you may qualify, or want to find a study site location near you, visit www.celiacdiseasestudy.com.